OX40-enhanced tumor rejection and effector T cell differentiation decreases with age

Por Ruby, Carl E., Weinberg, Andrew D.
Publicado no J Immunol (2009)

The role of OX40-mediated co-stimulation in T cell activation and survival

Por Redmond, William L., Ruby, Carl E., Weinberg, Andrew D.
Publicado em 2009

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

Por Kaufman, Howard L, Ruby, Carl E, Hughes, Tasha, Slingluff, Craig L
Publicado em 2014

OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in survival

Por Vasilevsky, Nicole A., Ruby, Carl E., Hurlin, Peter J., Weinberg, Andrew D.
Publicado em 2011

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin

Por Turturro, Sanja B., Najor, Matthew S., Ruby, Carl E., Cobleigh, Melody A., Abukhdeir, Abde M.
Publicado no Breast Cancer Res Treat (2016)

Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging

Por Farazi, Michelle, Nguyen, Justine, Goldufsky, Josef, Linnane, Stephanie, Lukaesko, Lisa, Weinberg, Andrew D., Ruby, Carl E.
Publicado em 2014

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival

Por Broucek, Joseph R, Hughes, Tasha, Huelsmann, Erica J, Poshepny, Joseph L, Ruby, Carl E, Zloza, Andrew, Kaufman, Howard L
Publicado em 2013

Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines

Por Goldufsky, Joe, Wood, Stephen, Hajihossainlou, Behnam, Rehman, Tooba, Majdobeh, Omar, Kaufman, Howard L., Ruby, Carl E., Shafikhani, Sasha H.
Publicado no J Med Microbiol (2015)

OX40 Agonists can drive Treg expansion if the cytokine milieu is right

Por Ruby, Carl E, Yates, Melissa A, Hirschhorn-Cymerman, Daniel, Chlebeck, Peter, Wolchok, Jedd D, Houghton, Alan N, Offner, Halina, Weinberg, Andrew D
Publicado no J Immunol (2009)

Oncolytic virus therapy for cancer

Por Goldufsky, Joe, Sivendran, Shanthi, Harcharik, Sara, Pan, Michael, Bernardo, Sebastian, Stern, Richard H, Friedlander, Philip, Ruby, Carl E, Saenger, Yvonne, Kaufman, Howard L
Publicado no Oncolytic Virother (2013)

A Preliminary Proteomic Investigation of Circulating Exosomes and Discovery of Biomarkers Associated with the Progression of Osteosarcoma in a Clinical Model of Spontaneous Disease...

Por Brady, Jacqueline V., Troyer, Ryan M., Ramsey, Stephen A., Leeper, Haley, Yang, Liping, Maier, Claudia S., Goodall, Cheri P., Ruby, Carl E., Albarqi, Hassan A.M., Taratula, Oleh, Bracha, Shay
Publicado no Transl Oncol (2018)

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade

Por Kohlhapp, Frederick J, Broucek, Joseph R, Hughes, Tasha, Huelsmann, Erica J, Lusciks, Jevgenijs, Zayas, Janet P, Dolubizno, Hubert, Fleetwood, Vidyaratna A, Grin, Alisa, Hill, Graham E, Poshepny, Joseph L, Nabatiyan, Arman, Ruby, Carl E, Snook, Joshua D, Rudra, Jai S, Schenkel, Jason M, Masopust, David, Zloza, Andrew, Kaufman, Howard L
Publicado no J Immunother Cancer (2015)

Signaling through OX40 Enhances Anti-tumor Immunity

Por Jensen, Shawn M., Maston, Levi D., Gough, Michael J., Ruby, Carl E., Redmond, William L., Crittenden, Marka, Li, Yuhuan, Puri, Sachin, Poehlein, Christian H., Morris, Nick, Kovacsovics-Bankowski, Magdalena, Moudgil, Tarsem, Twitty, Chris, Walker, Edwin B., Hu, Hong-Ming, Urba, Walter J., Weinberg, Andrew D., Curti, Brendan D, Fox, Bernard A.
Publicado em 2010